Enrollment paused on pembrolizumab trials in myeloma

The US pharmaceutical company, Merck, has announced that two of its trials (KEYNOTE-183 and KEYNOTE-185) investigating pembrolizumab (Keytruda┬«) treatment combinations for myeloma patients have paused new patient enrollment. Based on recommendations by the external data monitoring committee, additional information is being collected to better understand the increased reports of deaths in the pembrolizumab groups. Patients…

Details

FDA approves new daratumumab combination for myeloma patients

Genmab and Janssen have announced that the US Food and Drug Administration (FDA) has expanded the approval of daratumumab (Darzalex┬«) as part of a treatment combination for relapsed and/or refractory myeloma patients. Currently licensed by the FDA for use as a monotherapy for patients who have received at least three previous treatments or in combination…

Details